AQEMIA

📍 Paris, France🗓 Founded 2019👥 84 employees💰 Last funded Dec 2023
Biotechnology Research🌐 aqemia.com
Website LinkedIn
AQEMIA is a drug invention company dedicated to novel medicines — never me-toos — tackling major diseases such as oncology. Our physics-based, generative AI platform invents drug candidates beyond the reach of traditional R&D, without dependence on experimental data. We are building a rapidly expanding portfolio of proprietary programs, alongside collaborations with top pharmaceutical companies. Multiple discovery successes are already achieved, with lead programs progressing through in vivo optimization. AQEMIA is part of the French Tech 120 program, which supports the most promising scale-ups in France with global impact potential. AQEMIA is member of the BioIndustry Association (BIA) and the Knowledge Quarter in London. AQEMIA is based in Paris (HQ) and London. We are growing and hiring! Discover our opportunities here: https://jobs.lever.co/aqemia.com Discover the roles and behind-the-scenes at AQEMIA: https://www.welcometothejungle.com/fr/companies/aqemia
5
Total investors
3
Early stage
2
Mid stage
0
Late stage
2019
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
5
Investor activity2019–2023 · investors recorded per year
20191202122022120231
Recent (last 2y)Earlier
Frequently asked questions
Who invested in AQEMIA?
AQEMIA has 5 investors on record on gritt.io, including 3 early-stage backers, 2 mid-stage.
When did AQEMIA last raise funding?
The most recent investment in AQEMIA recorded on gritt.io was in December 2023.
When was AQEMIA founded?
AQEMIA was founded in 2019.
What industry is AQEMIA in?
AQEMIA operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AQEMIA based?
AQEMIA is headquartered in Paris, France.